Navigation Links
Dyadic International to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference
Date:5/10/2010

JUPITER, Fla., May 10 /PRNewswire-FirstCall/ -- Dyadic International, Inc. (Pink Sheets: DYAI) ("Dyadic"), a leading-edge early-stage biotechnology company, announced today that its President and Chief Executive Officer, Mark Emalfarb, is scheduled to present at the Rodman & Renshaw 6th Annual Global Healthcare Conference in London, England on Monday, May 17, 2010 at 11:05 a.m. local time (6:05 a.m. EDT). Mr. Emalfarb will discuss how Dyadic is applying its proprietary C1 platform technology for producing human antibodies and other high-value therapeutic proteins in addition to its other industrial uses for growth markets such as cellulosic ethanol, pulp & paper, animal feed, and starch and alcohol.

The PowerPoint presentation will be accessible after the conference on Dyadic's website at www.dyadic.com.

About Dyadic

Dyadic is a leading-edge early-stage biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries. In particular, Dyadic uses its Trichoderma and C1 fungal strains in the production of its industrial enzymes. Dyadic also utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost proteins and enzymes for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic aggressively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International Extends Collaboration With The Scripps Research Institute
2. Dyadic International Strengthens Management Team
3. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
4. The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
5. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
6. Arrow International Files and Mails Definitive Proxy Materials
7. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
8. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
9. Viragen International to Reverse Split Its Common Stock
10. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
11. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... the QB3@953 life sciences incubator to accelerate ... The shared laboratory space at QB3@953 was created to ... key obstacle for many early stage organizations - access ... the sponsorship, Amgen launched two "Amgen Golden Ticket" awards, ...
Breaking Biology Technology:
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
Breaking Biology News(10 mins):